151 related articles for article (PubMed ID: 10515877)
1. A novel approach to arterial thrombolysis.
Klement P; Liao P; Bajzar L
Blood; 1999 Oct; 94(8):2735-43. PubMed ID: 10515877
[TBL] [Abstract][Full Text] [Related]
2. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
[TBL] [Abstract][Full Text] [Related]
3. Inducible carboxypeptidase activity. A role in clot lysis in vivo.
Redlitz A; Nicolini FA; Malycky JL; Topol EJ; Plow EF
Circulation; 1996 Apr; 93(7):1328-30. PubMed ID: 8641019
[TBL] [Abstract][Full Text] [Related]
4. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
[TBL] [Abstract][Full Text] [Related]
6. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Mutch NJ; Moore NR; Wang E; Booth NA
J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
[TBL] [Abstract][Full Text] [Related]
7. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
8. Pre-administration of a carboxypeptidase inhibitor enhances tPA-induced thrombolysis in mouse microthrombi: Evidence from intravital imaging analysis.
Mathews NS; Suzuki Y; Honkura N; Sano H; Iwashita T; Urano T
Thromb Res; 2022 Feb; 210():78-86. PubMed ID: 35030422
[TBL] [Abstract][Full Text] [Related]
9. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
Bajzar L; Nesheim ME; Tracy PB
Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
[TBL] [Abstract][Full Text] [Related]
11. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
GuimarĂ£es AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
Mao SS; Holahan MA; Bailey C; Wu G; Colussi D; Carroll SS; Cook JJ
Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
[TBL] [Abstract][Full Text] [Related]
13. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.
Wang X; Smith PL; Hsu MY; Ogletree ML; Schumacher WA
J Thromb Haemost; 2006 Feb; 4(2):403-10. PubMed ID: 16420573
[TBL] [Abstract][Full Text] [Related]
14. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
Wang X; Smith PL; Hsu MY; Tamasi JA; Bird E; Schumacher WA
J Thromb Thrombolysis; 2007 Feb; 23(1):41-9. PubMed ID: 17111204
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
GuimarĂ£es AH; Barrett-Bergshoeff MM; Criscuoli M; Evangelista S; Rijken DC
Thromb Haemost; 2006 Sep; 96(3):325-30. PubMed ID: 16953274
[TBL] [Abstract][Full Text] [Related]
16. Serial thrombolysis-related changes after thrombolytic therapy with TPA in patients with acute myocardial infarction.
Ho CH; Wang SP
Thromb Res; 1990 May; 58(3):331-41. PubMed ID: 1693793
[TBL] [Abstract][Full Text] [Related]
17. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles.
Hashimoto M; Yamashita T; Oiwa K; Watanabe S; Giddings JC; Yamamoto J
Thromb Haemost; 2002 Jan; 87(1):110-3. PubMed ID: 11848438
[TBL] [Abstract][Full Text] [Related]
19. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.
Semeraro F; Ammollo CT; Semeraro N; Colucci M
Haematologica; 2009 Jun; 94(6):819-26. PubMed ID: 19377079
[TBL] [Abstract][Full Text] [Related]
20. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
Mutch NJ; Thomas L; Moore NR; Lisiak KM; Booth NA
J Thromb Haemost; 2007 Apr; 5(4):812-7. PubMed ID: 17388801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]